Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | PPARG | P37231 | 2/20 | 1.00 |
| ▸ | NCOA2 | Q15596 | 2/20 | 1.00 |
| ▸ | NCOA1 | Q15788 | 2/20 | 1.00 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | TYMP | P19971 | 1/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.66 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13984125 | 0.96 | ALDH1A1 (0.92) | ALDH1A1KDM4EPPARGNCOA2NCOA1 | |
| SCHEMBL17065364 | 0.82 | ALDH1A1 (0.69) | ALDH1A1KDM4EPPARGNCOA2NCOA1 | |
| SCHEMBL11862484 | 0.80 | TYMP (0.70) | ALDH1A1KDM4EPPARGNCOA2NCOA1 | |
| SCHEMBL30594886 | 0.80 | TYMP (0.70) | ALDH1A1KDM4EPPARGNCOA2NCOA1 | |
| SCHEMBL21144405 | 0.80 | ALDH1A1 (1.00) | ALDH1A1KDM4EPPARGNCOA2NCOA1 | |
| SCHEMBL4789246 | 0.78 | NOTUM (0.67) | ALDH1A1KDM4EPPARGNCOA2NCOA1 | |
| SCHEMBL29245313 | 0.77 | ALDH1A1 (0.60) | ALDH1A1KDM4EPPARGNCOA2NCOA1 | |
| SCHEMBL4238963 | 0.76 | MEN1 (1.00) | ALDH1A1KDM4EPPARGNCOA2NCOA1 | |
| SCHEMBL13984128 | 0.76 | NOTUM (0.66) | ALDH1A1KDM4EPPARGNCOA2NCOA1 | |
| SCHEMBL13984124 | 0.76 | NOTUM (0.66) | ALDH1A1KDM4EPPARGNCOA2NCOA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 504 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-1283278-A | — | — | None | — | — | JP | disclosed |
| CN-119816495-A | 1,3, 4-Oxadiazole derivative compounds as histone deacetylase 6 inhibitors and uses thereof | 株式会社钟根堂 | 2025-04-11 | — | — | CN | disclosed |
| EP-4398254-A2 | COMPOSITIONS AND METHODS FOR ALTERING SECOND MESSENGER SIGNALING | Memorial Sloan Kettering Cancer Center (US) | 2024-07-10 | — | — | EP | disclosed |
| US-12023371-B2 | Terminally modified RNA | MODERNATX, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-20240165267-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | ARES CAPITAL CORPORATION, AS AGENT | 2024-05-23 | — | — | US | disclosed |
| US-11987590-B2 | Compounds that participate in cooperative binding and uses thereof | Revolution Medicines, Inc. (US) | 2024-05-21 | — | — | US | disclosed |
| US-11981703-B2 | Polynucleotide constructs | SIRIUS THERAPEUTICS, INC. (US) | 2024-05-14 | — | — | US | disclosed |
| US-20240131193-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF CYTOPLASMIC AND CYTOSKELETAL PROTEINS | ARES CAPITAL CORPORATION, AS AGENT | 2024-04-25 | — | — | US | disclosed |
| US-20240123035-A1 | MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS | ARES CAPITAL CORPORATION, AS AGENT | 2024-04-18 | — | — | US | disclosed |
| EP-4351662-A1 | RADIOIMMUNOCONJUGATES AND CHECKPOINT INHIBITOR COMBINATION THERAPY | Fusion Pharmaceuticals Inc. (CA) | 2024-04-17 | — | — | EP | disclosed |
| WO-2013052523-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | modeRNA Therapeutics (US) | 2013-04-11 | — | — | WO | disclosed |
| EP-1000040-B1 | IL-5 INHIBITING 6-AZAURACIL DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2007-06-13 | — | — | EP | disclosed |
| US-20050090495-A1 | Novel IL-5 inhibiting 6-azauracil derivatives for marking and identifying receptors and imaging organs | LACRAMPE JEAN FERNAND ARMAND (FR) | 2005-04-28 | — | — | US | disclosed |
| US-6867207-B2 | IL-5 inhibiting 6-azauracil derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-03-15 | — | — | US | disclosed |
| US-20040167333-A1 | Novel IL-5 inhibiting 6-azauracil derivatives for marking and identifying receptors and imaging organs | LACRAMPE JEAN FERNAND ARMAND (FR) | 2004-08-26 | — | — | US | disclosed |
| US-20020072603-A1 | Novel IL-5 inhibiting 6-azauracil derivatives | LACRAMPE JEAN FERNAND ARMAND (FR) | 2002-06-13 | — | — | US | disclosed |
| EP-1000040-A1 | IL-5 INHIBITING 6-AZAURACIL DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-05-17 | — | — | EP | disclosed |
| WO-1999002505-A1 | IL-5 INHIBITING 6-AZAURACIL DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1999-01-21 | — | — | WO | disclosed |
| JP-H01283278-A | 4,4'-CARBONYLBIS(2-PHENYL-1,3,4-OXADIAZOLINE-5-THIONE) AND PRODUCTION THEREOF | NAKAMURA SHIGEO | 1989-11-14 | — | — | JP | disclosed |
| US-3971803-A | DISCOLORATION INHIBITION, POLYMER STABILIZERS | CIBA-GEIGY CORPORATION (US) | 1976-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11981703-B2 | Polynucleotide constructs | PHAX, CPSF6, RNGTT | ALDH1A1 3953/4885KDM4E 4658/4885PPARG 2961/4885 |
| US-20040167333-A1 | Novel IL-5 inhibiting 6-azauracil derivatives for marking and identifying receptors and imaging organs | IL6ST, CXCR5, ALOX5 | ALDH1A1 1219/4885KDM4E 3074/4885PPARG 418/4885 |
| US-11987590-B2 | Compounds that participate in cooperative binding and uses thereof | CEP170, PIN1, FKBP3 | ALDH1A1 4800/4885KDM4E 3972/4885PPARG 3502/4885 |
| US-20050090495-A1 | Novel IL-5 inhibiting 6-azauracil derivatives for marking and identifying receptors and imaging organs | CXCR5, HCAR3, IL6ST | ALDH1A1 1331/4885KDM4E 3799/4885PPARG 744/4885 |
| US-20240165267-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | ALDH1A1 1969/4885KDM4E 3519/4885PPARG 2844/4885 |
| US-20240131193-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF CYTOPLASMIC AND CYTOSKELETAL PROTEINS | PHAX, NSUN2, RNMT | ALDH1A1 4792/4885KDM4E 2455/4885PPARG 4329/4885 |
| US-12023371-B2 | Terminally modified RNA | RNGTT, NSUN3, RNMT | ALDH1A1 4235/4885KDM4E 495/4885PPARG 4188/4885 |
| US-20240123035-A1 | MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS | NSUN2, RNMT, NSUN3 | ALDH1A1 4488/4885KDM4E 4406/4885PPARG 3371/4885 |
| US-20020072603-A1 | Novel IL-5 inhibiting 6-azauracil derivatives | IL6ST, ALOX5, IL5 | ALDH1A1 848/4885KDM4E 2126/4885PPARG 853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.